Download full-text PDF |
Source |
---|
Eur J Dent
October 2021
Dental Science Department, Institute for Research and Training Advanced in Health Sciences and Technologies, Gandra, Portugal.
This study aimed to review clinical publications involving anterior-region resin-bonded fixed partial dentures to evaluate their survival rates vis-à-vis their materials and design. An electronic search was conducted using PubMed/MEDLINE to identify articles that reported on the longevity of anterior resin-bonded fixed dental prostheses published between 2000 and 2020. Only primary clinical studies that involved a follow-up after at least 3 years were included in this review.
View Article and Find Full Text PDFExp Hematol
August 2018
UMR E007, Service of Innovative Therapies, Institute of Biology François Jacob and University Paris Saclay, CEA Paris Saclay, Fontenay-aux-Roses, France; INSERM, Paris, France. Electronic address:
The β-hemoglobinopathies, transfusion-dependent β-thalassemia and sickle cell disease, are the most prevalent inherited disorders worldwide and affect millions of people. Many of these patients have a shortened life expectancy and suffer from severe morbidity despite supportive therapies, which impose an enormous financial burden to societies. The only available curative therapy is allogeneic hematopoietic stem cell transplantation, although most patients do not have an HLA-matched sibling donor, and those who do still risk life-threatening complications.
View Article and Find Full Text PDFInt Arch Allergy Immunol
May 2008
Department of Internal Medicine, Respiratory and Infectious Diseases, Charité Universitatsmedizin Berlin, Germany.
Background: Omalizumab is an established add-on therapy efficacious in allergic diseases with additional anti-inflammatory activity in the treatment of asthma. The evaluation of responders to anti-IgE treatment is critical to maximize benefit/risk/cost ratio. The aim of the study was to monitor the efficacy of anti-IgE treatment by ex vivo basophil histamine release.
View Article and Find Full Text PDFScand J Gastroenterol Suppl
August 1997
Dept. of Hepatogastroenterology, Erasmus University, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Background: Chronic hepatitis C can be treated with interferon therapy, but persistent viral clearance is only achieved in 20% of patients. Which patients have a high chance of viral clearance and what other treatment might enhance the effectivity of interferon therapy are reviewed.
Methods: Data from published randomized trials on interferon mono-therapy, ribavirin mono-therapy and combination therapy of interferon-ribavirin and interferon-ursodeoxycholic acid are analysed separately and in a meta-analysis of individual data.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!